The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response

BACKGROUND: Circulating cell-free DNA (cfDNA) may help understand the molecular response to pharmacologic treatment and provide information on dynamics of clonal heterogeneity. Therefore, this study evaluated the correlation between treatment outcome and activating EGFR mutations (act-EGFR) and T790...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Del Re, Marzia, Bordi, Paola, Rofi, Eleonora, Restante, Giuliana, Valleggi, Simona, Minari, Roberta, Crucitta, Stefania, Arrigoni, Elena, Chella, Antonio, Morganti, Riccardo, Tiseo, Marcello, Petrini, Iacopo, Danesi, Romano
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6251035/
https://ncbi.nlm.nih.gov/pubmed/30397287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0238-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados